Inventor · disambiguated record
Lizhen He
Also filed as: HE LIZHEN
15 granted patents·12 pending applications·130 citations·filing 2004–2024
92Inventor score
Top patents by PatentIndex Score
27 records- 0196US9169325B2Antibodies that bind human CD27 and uses thereofKELER TIBOR·Filed 2011·Granted Oct 27, 2015·64 cites·19 claims
- 0294US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 0391US8236318B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2008·Granted Aug 7, 2012·17 cites·19 claims
- 0490US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 0590US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 0689US9259459B2Antibody vaccine conjugates and uses thereforKELER TIBOR·Filed 2004·Granted Feb 16, 2016·21 cites·14 claims
- 0786US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0885US11180566B2Antibodies that bind human CD27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2015·Granted Nov 23, 2021·4 cites·7 claims
- 0985US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1082US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 1181US8362214B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2009·Granted Jan 29, 2013·3 cites·11 claims
- 1279US8586720B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2012·Granted Nov 19, 2013·3 cites·6 claims
- 1378US8318165B2Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)KELER TIBOR·Filed 2007·Granted Nov 27, 2012·2 cites·25 claims
- 1476US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1575US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1671US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 1771US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1870US2022227877A1Antibodies that bind human cd27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1964US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 2062US2009324622A1Antibody vaccine conjugates and uses thereforKELER TIBOR·Filed 2009·Application pending·0 cites
- 2160US9624300B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2012·Granted Apr 18, 2017·0 cites·5 claims
- 2255US2022016168A1Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapyCELLDEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2353US2016355593A1Antibody vaccine conjugates and uses thereforCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2452US2024368301A1MONOCLONAL ANTIBODY TARGETING SIRPa AND USE THEREOFHANGZHOU JIUYUAN GENE ENG CO LTD·Filed 2022·Application pending·0 cites
- 2548US2018044429A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2645US9243064B2Antibody vaccine conjugates and uses thereforKELER TIBOR·Filed 2004·Granted Jan 26, 2016·0 cites·16 claims
- 2741US2012213771A1Antibodies that bind human cd27 and uses thereofKELER TIBOR·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →